Morgan Stanley reiterated their overweight rating on shares of Agilent Technologies, Inc. (NYSE:A) in a research report released on Tuesday morning, MarketBeat reports.
A has been the subject of several other reports. Bank of America Corporation reaffirmed an equal weight rating on shares of Agilent Technologies in a report on Tuesday, August 15th. BidaskClub downgraded Agilent Technologies from a strong-buy rating to a buy rating in a report on Monday, July 31st. Deutsche Bank AG set a $68.00 price target on Agilent Technologies and gave the company a buy rating in a research report on Wednesday, August 16th. Goldman Sachs Group, Inc. (The) reissued a neutral rating and set a $68.00 price target on shares of Agilent Technologies in a research report on Tuesday, September 26th. Finally, J P Morgan Chase & Co reissued an overweight rating and set a $70.00 price target on shares of Agilent Technologies in a research report on Wednesday, August 16th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $66.70.
Shares of Agilent Technologies (NYSE A) opened at $68.79 on Tuesday. The company has a quick ratio of 2.76, a current ratio of 3.22 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $22,120.00, a price-to-earnings ratio of 29.46, a PEG ratio of 2.64 and a beta of 1.28. Agilent Technologies has a twelve month low of $42.92 and a twelve month high of $69.09.
Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Tuesday, August 15th. The medical research company reported $0.59 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.07. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the prior year, the firm posted $0.49 earnings per share. The company’s revenue was up 6.7% on a year-over-year basis. analysts forecast that Agilent Technologies will post 2.32 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was first reported by BBNS and is the property of of BBNS. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://baseballnewssource.com/markets/agilent-technologies-inc-a-earns-overweight-rating-from-morgan-stanley/1783169.html.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 24th. Shareholders of record on Tuesday, January 2nd will be given a $0.149 dividend. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.13. This represents a $0.60 annualized dividend and a yield of 0.87%. The ex-dividend date is Friday, December 29th. Agilent Technologies’s dividend payout ratio is presently 27.32%.
In other news, CFO Didier Hirsch sold 72,545 shares of the stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $62.38, for a total transaction of $4,525,357.10. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael R. Mcmullen sold 16,492 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $65.33, for a total value of $1,077,422.36. Following the transaction, the chief executive officer now directly owns 211,872 shares in the company, valued at approximately $13,841,597.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 140,292 shares of company stock worth $8,917,544.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Advisor Group Inc. boosted its stake in Agilent Technologies by 0.3% during the 2nd quarter. Advisor Group Inc. now owns 3,959 shares of the medical research company’s stock valued at $235,000 after purchasing an additional 10 shares during the period. Bronfman E.L. Rothschild L.P. boosted its stake in Agilent Technologies by 0.8% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,658 shares of the medical research company’s stock valued at $276,000 after purchasing an additional 35 shares during the period. Veritable L.P. boosted its stake in Agilent Technologies by 0.4% during the 2nd quarter. Veritable L.P. now owns 10,896 shares of the medical research company’s stock valued at $646,000 after purchasing an additional 40 shares during the period. Balentine LLC boosted its stake in Agilent Technologies by 2.9% during the 2nd quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock valued at $106,000 after purchasing an additional 50 shares during the period. Finally, Kingfisher Capital LLC boosted its stake in Agilent Technologies by 0.3% during the 2nd quarter. Kingfisher Capital LLC now owns 22,643 shares of the medical research company’s stock valued at $1,343,000 after purchasing an additional 58 shares during the period.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with our FREE daily email newsletter.